Polypeptide applied to inhibition of intracellular lipid accumulation and synthesis method thereof
US-2024366713-A1 · Nov 7, 2024 · US
Alphaa-crystallin mimetic peptides and uses thereof
US10220070B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10220070-B2 |
| Application number | US-201715707596-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 18, 2017 |
| Priority date | Sep 20, 2016 |
| Publication date | Mar 5, 2019 |
| Grant date | Mar 5, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates to αA-crystallin protein modulating compounds (e.g., phosphomimetic peptides), compositions comprising such modulating compounds, and their use as therapeutics for the treatment and prevention of conditions involving neurodegeneration and neuroinflammation.
First claim
Opening claim text (preview).
What is claimed is: 1. A composition comprising an αA-crystallin protein modulating compound, including pharmaceutically acceptable salts, solvates, and/or prodrugs thereof; wherein the αA-crystallin protein modulating compound is configured to mimic a phosphorylated wild type αA-crystallin protein, wherein said αA-crystallin protein modulating compound comprises a sequence of SEQ ID 1 having a threonine (T) to aspartic acid (D) or glutamate (E) substitution at amino acid position 148 or comprises a sequence of SEQ ID 2 with a serine (S) to aspartic acid (D) or glutamate (E) substitution at amino acid position 148. 2. A kit comprising a compound of claim 1 and instructions for administering said compound to a patient having or at risk for having diabetic retinopathy.
Assignees
Inventors
Classifications
- A61K38/16Primary
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)} · CPC title
substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone · CPC title
Eye, e.g. artificial tears · CPC title
Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10220070B2 cover?
- This invention relates to αA-crystallin protein modulating compounds (e.g., phosphomimetic peptides), compositions comprising such modulating compounds, and their use as therapeutics for the treatment and prevention of conditions involving neurodegeneration and neuroinflammation.
- Who is the assignee on this patent?
- Univ Michigan Regents, Univ Vanderbilt
- What technology area does this patent fall under?
- Primary CPC classification A61K38/16. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).